Big News!!! BIBP’s Inactivated Vaccine for Omicron Approved by UAE for Clinical Trial

      The vaccine has been approved by DoH Abu Dhabi, UAE for sequential immunization clinical studies, which will be performed in a randomized, double-blinded and controlled manner in enrolled volunteers aged above 18 who have received 2 or 3 doses of the prototype inactivated COVID-19 vaccine to evaluate the safety and immunogenicity of the vaccine. 

     Zhu Jingjin, head of global clinical trials for COVID-19 vaccine at CNBG, said that the clinical trials in the UAE would be supported by a good foundation and professional team, as well as experienced researchers. These trials could not only obtain complete data on safety and immunogenicity, but also cover more people in different countries, making the trial more comprehensive and authoritative.

      BIBP plays its role wherever there is an epidemic, fights against it till it perishes. Since the emergence of Omicron variant, CNBG has conducted scientific analysis, comprehensive research and judgment, and arranged its affiliate BIBP in advance to carry out the R&D. BIBP worked day and night, developed the inactivated vaccine for Omicron in the first place, and carried out clinical trials on the vaccine in different countries and regions. 

      The number of confirmed cases of COVID-19 worldwide has exceeded 500 million, with more than 6 million deaths. In face of the complicated and severe epidemic situation, Sinopharm CNBG BIBP will continue to make every effort to promote the clinical trials of vaccine for Omicron variant, pave the way for the early registration and marketing of the vaccine, and contribute more Chinese strength to building a community of common health for mankind.